Diurnal extends relationship with Consilient
UK-based specialty pharma firm Diurnal Group (AIM: DNL) said today that it has extended its distribution arrangements with Ireland-headquartered Consilient Health to include the distribution and marketing of Chronocort (modified-release hydrocortisone) in the Nordic region (consisting of Sweden, Norway, Denmark, Finland and Iceland).
Under the terms of this agreement, Consilient Health, a pharmaceutical company with a track record in commercializing products for endocrinology, women's health and urology, will receive the exclusive rights to market and sell Chronocort when approved, in the Nordics. The region represents a significant market opportunity for Diurnal, with around 2,300 adult patients suffering from congenital adrenal hyperplasia (CAH), providing an estimated total market opportunity for Chronocort of round 11.5 million euros ($14 million) per annum.
EMA marketing approval decision expected this quarter
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze